Alectinib Resistance in ALK-rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model

Molecular Cancer Research- United States

doi 10.1158/1541-7786.mcr-18-0325

Full Text

Abstract

Available in

Categories

Cancer Research

Molecular Biology

Date

August 31, 2018

Authors

Shunsuke Aburaya

Yasushi Yoshimura

Koichi Hasegawa

Hironori Yoshida

Yuichi Sakamori

Mitsuyoshi Ueda

Publisher

American Association for Cancer Research (AACR)

Related search

Molecular Mechanisms of Resistance to First- And Second-Generation ALK Inhibitors in ALK-rearranged Lung Cancer

European Journal of Cancer

Cancer Research

English

Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor

Clinical Cancer Research

Cancer Research

English

P1.01-009 Clinically Primary and Secondary Resistance to ALK Inhibitors in ALK-Positive Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Therapeutic Decision Based on Molecular Detection of Resistance Mechanism in an ALK-rearranged Lung Cancer Patient: A Case Report

OncoTargets and Therapy

English

Serial Liquid Biopsies for Detection of Treatment Failure and Profiling of Resistance Mechanisms in KLC1-ALK Rearranged Lung Cancer

Cold Spring Harbor molecular case studies

Molecular Medicine

English

Pcn172 - Cost-Effectiveness Analysis of Alectinib in Untreated Alk-Rearranged NSCLC Italian Patients

Value in Health

Occupational Health

English

Nicotinic-nAChR Signaling Mediates Drug Resistance in Lung Cancer

Journal of Cancer

German

Dramatic Response to Alectinib in a Lung Cancer Patient With a Novel VKORC1L1-ALK Fusion and an Acquired ALK T1151K Mutation

Lung Cancer: Targets and Therapy

English

Drug Resistance in Lung Cancer

Lung Cancer: Targets and Therapy

German